This study found that there was no benefit from Ifn-beta or Copaxone in preventing a postpartum relapse.
http://www.neurology.org/cgi/content/me ... ts/P06.192Quote:
...resuming treatment with bIFN or GA even as early as 2 weeks postpartum did not decreased the risk of relapse in the 2 years postpartum compared with women who resumed treatment later in the postpartum year (p=0.90 unadjusted; PS-adjusted HR=1.2, 95%CI=0.59-2.56, p=0.6).
Conclusions: Our findings suggest that starting bIFN or GA even within two weeks postpartum does not reduce the risk of postpartum relapses. Our findings call into question the benefit of early resumption of MS treatments in lieu of breastfeeding and should be confirmed in a larger study.